Active
Company Information for NERRE THERAPEUTICS HOLDINGS LIMITED
Stevenage Bioscience Catalyst, Incubator Building, Gunnels Wood Road, Stevenage, HERTFORDSHIRE, SG1 2FX,
|
Company Registration Number
![]() Private Limited Company
Active |
Company Name | |
---|---|
NERRE THERAPEUTICS HOLDINGS LIMITED | |
Legal Registered Office | |
Stevenage Bioscience Catalyst, Incubator Building Gunnels Wood Road Stevenage HERTFORDSHIRE SG1 2FX | |
Company Number | 10753026 | |
---|---|---|
Company ID Number | 10753026 | |
Date formed | 2017-05-03 | |
Country | UNITED KINGDOM | |
Origin Country | United Kingdom | |
Type | Private Limited Company | |
CompanyStatus | Active | |
Lastest accounts | 2024-06-30 | |
Account next due | 2026-03-31 | |
Latest return | 2025-06-25 | |
Return next due | 2026-07-09 | |
Type of accounts | SMALL | |
VAT Number /Sales tax ID | GB277385165 |
Last Datalog update: | 2025-07-01 15:49:11 |
Companies House |
Menu
|
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help. Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. |
Officer | Role | Date Appointed |
---|---|---|
IAIN DAVID DUKES |
||
ANDREW KAY |
||
MARY KERR |
||
SAIYED KAASIM MAHMOOD |
||
GEERT JAN MULDER |
||
ENA PROSSER |
Officer | Role | Date Appointed | Date Resigned |
---|---|---|---|
MICHAEL KEITH TROWER |
Director |
Officer | Related Company | Role | Date Appointed | Role Status | Incorporation date | Company Status |
---|---|---|---|---|---|---|
KANDY THERAPEUTICS LIMITED | Director | 2017-09-14 | CURRENT | 2017-05-03 | Active | |
REVIRAL LIMITED | Director | 2016-12-22 | CURRENT | 2011-01-10 | Active | |
NERRE THERAPEUTICS LTD | Director | 2016-12-22 | CURRENT | 2012-01-19 | Active | |
NERRE THERAPEUTICS LTD | Director | 2017-09-15 | CURRENT | 2012-01-19 | Active | |
KANDY THERAPEUTICS LIMITED | Director | 2017-09-14 | CURRENT | 2017-05-03 | Active | |
NERRE THERAPEUTICS LTD | Director | 2015-10-01 | CURRENT | 2012-01-19 | Active | |
CAUSEWAY LIFE SCIENCES CONSULTANTS LTD | Director | 2015-06-30 | CURRENT | 2015-06-30 | Active | |
KANDY THERAPEUTICS LIMITED | Director | 2017-09-14 | CURRENT | 2017-05-03 | Active | |
VENTUS MEDICAL LIMITED | Director | 2015-07-03 | CURRENT | 2014-12-22 | Active | |
NERRE THERAPEUTICS LTD | Director | 2013-03-12 | CURRENT | 2012-01-19 | Active | |
KANDY THERAPEUTICS LIMITED | Director | 2017-09-14 | CURRENT | 2017-05-03 | Active | |
KANDY THERAPEUTICS LIMITED | Director | 2017-09-14 | CURRENT | 2017-05-03 | Active | |
NERRE THERAPEUTICS LTD | Director | 2016-12-22 | CURRENT | 2012-01-19 | Active |
Date | Document Type | Document Description |
---|---|---|
SMALL COMPANY ACCOUNTS MADE UP TO 30/06/24 | ||
CONFIRMATION STATEMENT MADE ON 25/06/25, WITH UPDATES | ||
CONFIRMATION STATEMENT MADE ON 25/06/24, WITH UPDATES | ||
Director's details changed for Mr Andrew Kay on 2024-04-09 | ||
SMALL COMPANY ACCOUNTS MADE UP TO 30/06/23 | ||
05/09/23 STATEMENT OF CAPITAL GBP 3630.8867 | ||
Cancellation of shares. Statement of capital on 2023-08-31 GBP 3,619.97775 | ||
Purchase of own shares | ||
CONFIRMATION STATEMENT MADE ON 25/06/23, WITH NO UPDATES | ||
Director's details changed for Mr Javier García Cogorro on 2021-06-25 | ||
Director's details changed for Mr Andrew Kay on 2023-03-01 | ||
Director's details changed for Dr Ena Prosser on 2019-04-15 | ||
SMALL COMPANY ACCOUNTS MADE UP TO 30/06/22 | ||
23/06/22 STATEMENT OF CAPITAL GBP 3623.3456 | ||
CONFIRMATION STATEMENT MADE ON 25/06/22, WITH UPDATES | ||
AA | SMALL COMPANY ACCOUNTS MADE UP TO 30/06/21 | |
SH01 | 09/11/21 STATEMENT OF CAPITAL GBP 3603.8224 | |
CS01 | CONFIRMATION STATEMENT MADE ON 25/06/21, WITH UPDATES | |
SH03 | Purchase of own shares | |
SH06 | Cancellation of shares. Statement of capital on 2021-06-25 GBP 1,813.002955 | |
PSC08 | Notification of a person with significant control statement | |
RES09 | Resolution of authority to purchase a number of shares | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
SH01 | 25/06/21 STATEMENT OF CAPITAL GBP 3413.387855 | |
AA | SMALL COMPANY ACCOUNTS MADE UP TO 30/06/20 | |
AP01 | DIRECTOR APPOINTED MR JAVIER GARCíA COGORRO | |
PSC07 | CESSATION OF ADVENT LIFE SCIENCES LLP AS A PERSON OF SIGNIFICANT CONTROL | |
CS01 | CONFIRMATION STATEMENT MADE ON 02/05/21, WITH NO UPDATES | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
RES10 | Resolutions passed:
| |
CS01 | CONFIRMATION STATEMENT MADE ON 02/05/20, WITH UPDATES | |
AA | FULL ACCOUNTS MADE UP TO 30/06/19 | |
SH10 | Particulars of variation of rights attached to shares | |
SH08 | Change of share class name or designation | |
CS01 | CONFIRMATION STATEMENT MADE ON 02/05/19, WITH UPDATES | |
SH01 | 29/01/19 STATEMENT OF CAPITAL GBP 1813.2943 | |
AA | FULL ACCOUNTS MADE UP TO 30/06/18 | |
RES10 | Resolutions passed:
| |
SH01 | 23/11/18 STATEMENT OF CAPITAL GBP 1806.92930 | |
SH06 | Cancellation of shares. Statement of capital on 2018-11-23 GBP 1,806.93 | |
SH03 | Purchase of own shares | |
CS01 | CONFIRMATION STATEMENT MADE ON 02/05/18, WITH UPDATES | |
PSC02 | Notification of Advent Life Sciences Llp as a person with significant control on 2017-09-08 | |
LATEST SOC | 20/03/18 STATEMENT OF CAPITAL;GBP 1392.34955 | |
SH01 | 15/03/18 STATEMENT OF CAPITAL GBP 1392.34955 | |
LATEST SOC | 24/01/18 STATEMENT OF CAPITAL;GBP 1392.22455 | |
SH01 | 22/01/18 STATEMENT OF CAPITAL GBP 1392.22455 | |
RES01 | ADOPT ARTICLES 12/12/17 | |
AP01 | DIRECTOR APPOINTED MR ANDREW KAY | |
SH02 | Sub-division of shares on 2017-09-08 | |
AP01 | DIRECTOR APPOINTED DR IAIN DAVID DUKES | |
AP01 | DIRECTOR APPOINTED DR ENA PROSSER | |
AP01 | DIRECTOR APPOINTED DR GEERT JAN MULDER | |
AP01 | DIRECTOR APPOINTED DR SAIYED KAASIM MAHMOOD | |
PSC07 | CESSATION OF MICHAEL KEITH TROWER AS A PERSON OF SIGNIFICANT CONTROL | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR MICHAEL KEITH TROWER | |
AP01 | DIRECTOR APPOINTED DR MARY KERR | |
SH01 | 08/09/17 STATEMENT OF CAPITAL GBP 2728.8121 | |
SH08 | Change of share class name or designation | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
RES11 | DISAPPLICATION OF PRE-EMPTION RIGHTS | |
RES01 | 08/09/2017 | |
RES12 | Resolution of varying share rights or name | |
SH08 | Change of share class name or designation | |
RES12 | VARYING SHARE RIGHTS AND NAMES | |
RES01 | ADOPT ARTICLES 14/09/2017 | |
SH20 | STATEMENT BY DIRECTORS | |
LATEST SOC | 14/09/17 STATEMENT OF CAPITAL;GBP 1364.40605 | |
SH19 | 14/09/17 STATEMENT OF CAPITAL GBP 1364.40605 | |
CAP-SS | SOLVENCY STATEMENT DATED 14/09/17 | |
RES13 | REDUCTION OF THE SHARE PREMIUM ACCOUNT 14/09/2017 | |
RES06 | REDUCE ISSUED CAPITAL 14/09/2017 | |
AA01 | CURREXT FROM 31/05/2018 TO 30/06/2018 | |
LATEST SOC | 03/05/17 STATEMENT OF CAPITAL;GBP .0001 | |
NEWINC | CERTIFICATE OF INCORPORATION GENERAL COMPANY DETAILS & STATEMENTS OF; OFFICERS, CAPITAL & SHAREHOLDINGS, GUARANTEE, COMPLIANCE MEMORANDUM OF ASSOCIATION ARTICLES OF ASSOCIATION |
Total # Mortgages/Charges | 0 |
---|---|
Mortgages/Charges outstanding | 0 |
Mortgages Partially Satisifed | 0 |
Mortgages Satisfied/Paid | 0 |
Average | Max |
This shows the max and average number of mortgages for companies with the same SIC code of 72110 - Research and experimental development on biotechnology
The top companies supplying to UK government with the same SIC code (72110 - Research and experimental development on biotechnology) as NERRE THERAPEUTICS HOLDINGS LIMITED are:
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help. Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. |